Ampio Pharmaceuticals

The COVID-19 vaccine frenzy has swept up a slew of small pharmaceutical and biotech names. That's good news for a lot of these smaller companies. Even if they are only minor players, they receive coverage. This helps them gain attention within the industry and from investors.

This is what happened to AMPE. Its anti-inflammatory drug Ampion, which is being tested for osteoarthritis, has been approved for use in COVID-19 patients with respiratory issues. The company is currently conducting an IV trial and has recently begun research on an inhalable version.

It also has another drug in development for diabetic macular edema, which affects approximately 600,000 patients in the United States each year.

Year to date, the stock is up 42 percent.

Website: ampiopharma.com

Market Cap: 117.608M